Abstract:Abstract Glioblastoma (GBM) is the most common and deadly adult brain cancer with a post-diagnosis survival of 8-15 months even with treatment, highlighting a desperate need for new therapeutic strategies. One promising strategy involves the use of chimeric antigen receptor T-cell (CAR-T) therapy, created by engineering patient T-cells to express a CAR that recognizes a tumor-specific surface antigen thus allowing for directed tumor cell killing. While CAR-T therapy has experienced unprecedented success in treating hematologic malignancies, its application in solid tumors has proven challenging. However, early clinical studies in GBM have shown promise including a case in which a patient with disseminated GBM experienced a complete response. Unfortunately, the patient relapsed highlighting both potential therapeutic efficacy and our limited knowledge of resistance and relapse mechanisms. Established resistance mechanisms include tumor target antigen loss or intrinsic CAR-T failure, but there are certainly others that have yet to be identified. Furthermore, solid tumors present unique challenges and may possess distinctive resistance mechanisms related to hostile, immunosuppressive tumor microenvironments and vast inter-tumoral heterogeneity. Ultimately, improved understanding could lead to increased therapeutic efficacy through CAR-T combination therapies or direct CAR-T cell modifications. Beyond the promise of CAR-T however, there still remains a scarcity of effective treatment options for GBM, underscoring a critical need to gain a better fundamental understanding in order to create additional novel therapeutic strategies. In order to both understand mechanisms of resistance to CAR-T therapy in GBM and uncover novel tumor dependencies for therapeutic exploitation, I took an unbiased, functional genomics approach. I conducted a series of in vivo genome-wide screens in an orthotopic, immunocompetent mouse model of GBM using a novel, modular, small-pooled CRISPR/Cas9 single guide (sgRNA) library. Cas9-expressing tumor cells with library sgRNAs were intracranially injected into mice that subsequently received no treatment or direct intertumoral injection of non-targeting control or targeting CAR-T cells. Top depletion and enrichment hits were used to generate 2 separate validation libraries one containing CAR-T sensitization or resistance hits and the other containing hits essential for in vivo tumor growth and therefore potentially exploitable as novel therapeutic targets. Validation libraries were screened in the same manner as the original genome-wide screen and top hits are actively being validated with planned in-depth mechanistic follow up. Importantly, to date, these are the first in vivo genome-wide CRISPR/Cas9 screens conducted in an orthotopic, immunocompetent mouse model of GBM. Ultimately, these results could aid not only in the identification of novel therapeutic strategies for GBM and potential improvements in CAR-T clinical efficacy, but also in a broader understanding of the fundamental biology that underlies treatment resistance in GBM. Citation Format: Catherine E. Koch, Charles A. Whittaker, Michael T. Hemann. In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr PR-003.

Exth-16. Unbiased Discovery Of Synergistic Vulnerabilities Against Glioblastoma: An Innovativein Vivo Crispr Profiling Platform To Unleash The Power Of Tumor-Targeted Cytokine Therapy

Abstract 5460: Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Abstract PR-003: In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy

Dddr-42. Leveraging Genome-Wide Crispr/Cas9 Knockout Drug Screens To Identify Sensitizers For Proteosome Inhibitors In Glioblastoma

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Dddr-17. A Facile High Throughput Drug Screening Platform Enables The Construction Of A Pharmaco-Proteogenomic Interaction Landscape In Glioblastoma

Dddr-05. Spatially Resolved Drug Sensitivity Profiling In Glioblastoma

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells

Abstract 4304: Network-based inference identifies cell state-specific drugs targeting master regulator vulnerabilities in diffuse midline glioma

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma

BIOM-35. A NEW PRECISION-MEDICINE APPROACH TO PREDICT TUMOR TREATMENT RESPONSE IDENTIFIES IN GLIOBLASTOMA A 17 GENE SIGNATURE PROGNOSTIC OF TMZ RESPONSE AND SURVIVAL WITH ROBUST PREDICTIVE VALUE

Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data

Abstract 5841: A genome wide CRISPR-Cas9 screen identifies mediators of resistance to dual PI3K/mTOR inhibition in glioblastoma multiforme

Dddr-34. A Systems Medicine Platform For Individualized Treatment Of Glioblastoma

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes

Immu-62. Invigorating Effector Immune Cells With Highly Selective Il-2R Agonists And Potential Synergy With Tumor Targeting Therapeutics For Treatment Of Glioblastomas

Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas

Ddel-16. Micromesh For Revamping The 'Cold' Tumor Microenvironment In Glioblastoma Immunotherapy

Abstract 3106: Integrated in vitro and machine learning approaches for targeted drug screening in gliomas with concurrent NF1 and ATRX loss